DoD Peer Reviewed, Career Development Award
Funding Agency:
- Department of Defense
The PRCRP is seeking to advance cancer research through development of early-career investigators. Dependent on the accomplishments of candidates, the PRCRP will offer two distinct early-career development options: the Fellow Option (CDA-FO) and the Virtual Cancer Center Scholar Option (CDA-SO). Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI’s research and career development. Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated. This award supports impactful research projects with an emphasis on discovery.
○ Fellow Option: The PI must be an early-career researcher or physician-scientist (referred to as a Fellow) within 7 years after completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training, or on family medical leave). Principal Investigators suitable for the Fellow Option include investigators who may not be on a tenure track and may only have laboratory space but not a completely separate laboratory from a more established investigator. The intention of the Fellow Option is to support the early-career investigators toward wider independence and success.
○ Virtual Cancer Center Scholar Option: Supports an independent, highly accomplished early-career investigator (referred to as a Scholar) to conduct impactful research under the guidance of an experienced cancer researcher (i.e., Career Guide). Scholars will commit to participate in the FY20 PRCRP Virtual Cancer Center (VCC) (CSVCC – Convergent Science Virtual Cancer Center). The unique, interactive VCC focuses on fostering the next generation of cancer researchers. This award provides intensive mentoring, national networking, and a peer group for junior faculty. Scholars are required to interact with the VCC Director, Deputy Director, and fellow Scholars in addition to their Career Guide. The intention of the Scholar Option is to support the highly accomplished investigator toward the goal of leadership in cancer.
It is the responsibility of the PI to select the option that best aligns with their current career stage. The option should be selected based on the eligibility defined in the program announcement, and not on the amount of the budget. It is incumbent upon the early-career investigator to select the suitable option.
The anticipated direct costs budgeted for the entire period of performance for an FY22 PRCRP CDA-FO Award will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The anticipated direct costs budgeted for the entire period of performance for an FY22 PRCRP CDA-SO Award will not exceed $800,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
The FY22 appropriation is $130M.
11:59 p.m. ET, August 2, 2022
CDMRP Help Desk, Phone: 301-682-5507, Email: help@eBRAP.org